{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.72","value":"3.42"},{"groupId":"OG001","spread":"2.20","value":"3.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.86","value":"4.92"},{"groupId":"OG001","spread":"2.67","value":"3.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 2 Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.70","value":"2.63"},{"groupId":"OG001","spread":"0.45","value":"0.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 2 Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.35","value":"1.55"},{"comment":"Only 1 patient had a result at this time point and the standard deviation was not calculated.","groupId":"OG001","spread":"NA","value":"0.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 2 Day 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Mean and Standard Deviation of the Graft Composition of Peripheral Blood Stem Cell Collection (CD34 (x10\\^6cells/kg)) at each time point collected during Cycle 2.","dispersionType":"Standard Deviation","groups":[{"description":"This is for the patients with Multiple Myeloma.\n\nMeloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.\n\n15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.\n\n10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection.\n\nMeloxicam: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.\n\nFilgrastim: Filgrastim will be subcutaneously injected in one or two sites at home.","id":"OG000","title":"Multiple Myeloma"},{"description":"This is for the patients with Non Hodgkins Lymphoma.\n\nMeloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.\n\n15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.\n\n10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection.\n\nMeloxicam: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.\n\nFilgrastim: Filgrastim will be subcutaneously injected in one or two sites at home.","id":"OG001","title":"Non Hodgkins Lymphoma"}],"paramType":"MEAN","populationDescription":"Patients with available post-transplant CD34 (x10\\^6/kg) data.","reportingStatus":"POSTED","timeFrame":"Cycle 2, Days 1-4, within 100 days of transplant","title":"Summary Statistics for Graft Composition of Peripheral Blood Stem Cell Collection at Each Time Point","type":"SECONDARY","unitOfMeasure":"x10^6cells/kg"}